<DOC>
	<DOC>NCT01664637</DOC>
	<brief_summary>The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered for 12 weeks, in diabetic subjects with symptoms associated with gastroparesis.</brief_summary>
	<brief_title>Diabetic Gastroparesis Efficacy/Safety Study of TZP-102</brief_title>
	<detailed_description />
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>18 to 80 years of age inclusive Type 1 or type 2 diabetes mellitus History of symptoms of gastroparesis for at least 3 months leading up to the Screening Visit Documented delayed gastric emptying Upper gastrointestinal obstruction ruled out by endoscopy or barium scan Concomitant medications must be stable for at least 2 weeks leading up to the Screening visit and must be maintained during the study. Females of childbearing potential must have a negative serum pregnancy test and use (and agree to continue to use throughout the study) an acceptable form of contraception Gastrectomy, bariatric surgery, fundoplication or vagotomy/pyloroplasty Has had or plans to have endoscopic pyloric injections of botulinum toxin within 6 months prior to the Screening Visit or during the study NG, PEG or PEJ feeding tube or inpatient hospitalization for gastroparesis within 2 weeks prior to the Screening Visit Required parenteral nutrition for treatment of gastroparesis within 2 months prior to the Screening Visit Active gastric pacemaker within 3 months prior to the Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>diabetic gastroparesis</keyword>
	<keyword>delayed gastric emptying</keyword>
	<keyword>gastroparesis</keyword>
	<keyword>diabetes mellitus, Type 1</keyword>
	<keyword>diabetes mellitus, Type 2</keyword>
</DOC>